SHAREHOLDER ALERT: WeissLaw LLP Investigates Akcea Therapeutics, Inc.

NEW YORK, Aug. 31, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akcea Therapeutics, Inc. ("AKCA" or the "Company") (NASDAQ: AKCA) in connection with the proposed interested-party acquisition of the Company by Ionis Pharmaceuticals, Inc. ("IONS") (NASDAQ: IONS), pursuant to which IONS will acquire all of the minority shares of AKCA that it does not already own.  Under the terms of the acquisition agreement, which is structured as a tender offer, the Company's shareholders will receive $18.15 in cash for each share of AKCA common stock that they own.   If you own AKCA shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: https://www.weisslawllp.com/akcea-therapeutics-inc/ Or please contact:Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY  10036(212) 682-3025(888) 593-4771stockinfo@weisslawllp.com In light of the fact that IONS already controls 76% of AKCA's common stock, WeissLaw is investigating whether AKCA's board was truly independent and fully informed as to the valuation of the proposed acquisition of the Company, whether the board acted to maximize shareholder value prior to entering into the acquisition agreement, and whether all information To keep reading about SHAREHOLDER ALERT: WeissLaw LLP Investigates Akcea Therapeutics, Inc., Click on the link. Seoul, Korea
http://dlvr.it/RfkLMF